Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- Cancer Research and Treatment52(1) · pp.277 · 2020
- 피인용
- Web of Science 30Scopus 32KCI 1
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 3.761
- ISSN
- 1598-2998
저자
- Lee, Hee Yeon제1저자Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul
- Hong, Ji HyungDepartment of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul
- Byun, Jae Ho교신저자Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon
- Kim, Hee-JunDepartment of Internal Medicine, Chung-Ang University College of Medicine, Seoul
- Baek, Sun KyungDepartment of Internal Medicine, Kyung Hee University School of Medicine, Seoul
- Kim, Jin YoungDepartment of Hemato-Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu
- Kim, Ki HyangDepartment of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan
- Yun, JinaDepartment of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon
- Kim, Jung A.Department of Internal Medicine, Kyung Hee University Gangdong Hospital, Seoul
- 박권오Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan
- Lee, Hyo JinDepartment of Internal Medicine, Chungnam National University College of Medicine, Daejeon
- Lee, Jung LimDepartment of Hemato-oncology, Daegu Fatima Hospital, Daegu
- Won, Young-WoongDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul
- Kim, Il HwanDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan
- Bae, Woo KyunDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun
- Park, Kyong HwaDepartment of Internal Medicine, Korea University College of Medicine, Seoul
- Sun, Der-ShengDepartment of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu
- Lee, SueeDepartment of Internal Medicine, Dong-A University Hospital, Busan
- Lee, Min-YoungDepartment of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul
- Lee, Guk JinDepartment of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon
- Hong, Sook HeeDepartment of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul
- Jung, Yun HwaSun General Hospital, Daejeon
- An, Ho JungDepartment of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
초록
Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease <= 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
키워드
Ovarian epithelial carcinomaClear cell adenocarcinomaKoreaAdjuvant chemotherapyPROGRESSION-FREE SURVIVALADJUVANT CHEMOTHERAPYARID1A EXPRESSIONENDOMETRIOSISCARCINOMAMUTATIONSPROGNOSISCOHORTEVENT
식별자
- Scopus EID
- 2-s2.0-85077934315
- WoS UID
- 000507387500024
- KCI
- ART002549163



로그인
연구물 목록으로